雑誌文献を検索します。書籍を検索する際には「書籍検索」を選択してください。

検索

書誌情報 詳細検索 by 医中誌

Japanese

Up-to-Date Oral Anticoagulants Hidehiko HARA 1 1Division of Cardiovascular Medicine, Toho University Ohashi Medical Center Keyword: DOAC , stroke , high bleeding risk , atrial fibrillation pp.426-432
Published Date 2025/7/10
DOI https://doi.org/10.18916/masui.2025070005
  • Abstract
  • Look Inside
  • Reference

 The oral anticoagulants we use in our daily clinical practice have changed significantly over the past 10 years. In most cases of atrial fibrillation and venous thromboembolism, we have moved from the traditional vitamin K antagonist warfarin to the new direct oral anticoagulants(DOACs). DOACs are generally classified into two types. The first is thrombin(factor Ⅱa)inhibitors such as Dabigatran(Pradaxa®). In Japan, Idarucizumab(Praxbind®)is used as a reversal agent. The second type is factor Xa inhibitors, including Rivaroxaban(Xarelto®), Apixaban(Eliquis®), and Edoxaban(Lixiana®);these are used by more patients. Andexanet alfa(Ondexxya®)can be used as a reversal agent. While the reversal drug for warfarin was traditionally intravenous vitamin K, the recent launch of Kaycentra®, an intravenous prothrombin complex preparation, has moved us into an era where we can expect a quicker effect than with vitamin K administration. In this article, we discuss the current patient profile necessitating caution when using DOACs and DOAC antagonists.


Copyright © 2025 KOKUSEIDO CO., LTD. All Rights Reserved.

基本情報

電子版ISSN 印刷版ISSN 0021-4892 克誠堂出版

関連文献

もっと見る

文献を共有